DongKook Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 14, 2023 at 02:09 pm IST
Share
DongKook Pharmaceutical Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was KRW 1,606.28 million compared to KRW 5,387.57 million a year ago. Net income was KRW 12,134.31 million compared to KRW 11,816.95 million a year ago. Basic earnings per share from continuing operations was KRW 276 compared to KRW 269 a year ago. Diluted earnings per share from continuing operations was KRW 271 compared to KRW 264 a year ago. Basic earnings per share was KRW 276 compared to KRW 269 a year ago. Diluted earnings per share was KRW 271 compared to KRW 264 a year ago.
For the nine months, sales was KRW 9,516.92 million compared to KRW 17,468.61 million a year ago. Net income was KRW 38,109.72 million compared to KRW 43,531.34 million a year ago. Basic earnings per share from continuing operations was KRW 867 compared to KRW 990 a year ago. Diluted earnings per share from continuing operations was KRW 852 compared to KRW 973 a year ago. Basic earnings per share was KRW 867 compared to KRW 990 a year ago. Diluted earnings per share was KRW 852 compared to KRW 973 a year ago.
DongKook Pharmaceutical Co., Ltd. is a Korea-based company engaged in the development, manufacture and distribution of pharmaceuticals. The Company develops and provides remedies for oral troubles, skin troubles and gynecology diseases, contrast mediums, anesthetics, anticancer medicines and circulatory system agents. It also provides other pharmaceuticals, such as remedies for arthritis and pancreatitis, antiphlogistic, anodynes, antibiotics and vitamins, as well as raw materials for pharmaceuticals. In addition, it is engaged in the rental business. The Company distributes its products within domestic market and to overseas markets, such as Japan, Germany, India, Brazil and Mexico, among others.